Related Experiment Video
Updated: Feb 20, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Pravastatin for prevention of HELLP syndrome: A case report
Lucia Anna Otten1, Katrin van der Ven, Marietta Kühr
1Department of Obstetrics and Prenatal Medicine Department of Gynecologic Endocrinology and Reproductive Medicine, University Bonn Medical School, Bonn, Germany.
Rationale:
Pravastatin has emerged for prevention and treatment of preeclampsia; no reports are available on pravastatin and HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome.
Patient Concerns:
The first pregnancy necessitated termination of pregnancy at gestational age (GA) 20+5 for HELLP. Intrauterine fetal death at GA 22+5 occurred in the second pregnancy, whilst on temporizing management of HELLP.
Diagnoses:
Severe, recurrent early-onset HELLP syndrome.
Interventions:
In her fourth pregnancy, pravastatin was commenced at GA 13.
Outcomes:
The course of pregnancy was uncomplicated, and a healthy, appropriate for gestational age fetus was delivered at term.
Lessons:
Pravastatin may be effective in prevention of HELLP. The hepatic uptake may be of particular advantage.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Atherosclerosis IV: Nursing Management
Coronary Artery Disease IV: Preventive Measures

